3 news items
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
MBRX
9 May 24
and Chairman of Moleculin, stated, "We remain committed to establishing a robust patent estate for Annamycin and driving its development forward
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
MBRX
1 May 24
programs with the formation of this Scientific Advisory Board and add the internationally-renowned knowledge and expertise of Dr. Tallman. We are committed
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
MBRX
10 Apr 24
. We remain highly encouraged by Annamycin and committed to advancing its development," concluded Mr. Klemp
- Prev
- 1
- Next